ArticleCancer medicine2026
Development and Validation of an AI-Assisted Predictive Model Integrating R2* Mapping and Clinical Indicators for Clinically Significant Prostate Cancer.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NN-assisted image analysis for quantifying intracellularFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLimited evidence exists on the diagnostic performance of Artificial Intelligence (AI)-assisted Simplified Prostate Imaging Reporting and Data System version 2.1 (S-PI-RADS v2.1) combined with quantitative MRI parameters for detecting clinically significant prostate cancer (csPCa). PURPOSE: To develop and validate a nomogram incorporating AI-assisted S-PI-RADS v2.1 (based on biparametric MRI [bpMRI]) and R2* mapping for csPCa prediction.
methodsThis prospective study enrolled 345 patients grouped by pathology: non-csPCa with benign prostatic hyperplasia (n = 230) and csPCa (n = 115). Clinical (age, body mass index [BMI], prostate-specific antigen [PSA], free PSA) and imaging parameters (prostate volume [PV], S-PI-RADS score, R2*) were analyzed. Independent predictors were identified via logistic regression. A nomogram was developed using R software with the DynNom package (Version 2.0) and validated (1000 bootstrap iterations), with performance assessed by area under the curve (AUC), calibration, decision curve analysis (DCA), and DeLong test (p < 0.05 significant).
resultsIndependent csPCa predictors included BMI, PSA ≥ 10 ng/mL, PV, S-PI-RADS scores 4-5, and R2* (all p < 0.05). The full model (BMI + PSA + PV + S-PI-RADS + R2*) showed superior discrimination (AUC = 0.915) versus the baseline model (AUC = 0.891, p = 0.008), with 85.2% sensitivity and 80.9% specificity. Internal validation was robust (C-index = 0.884). DCA confirmed clinical utility. An interactive nomogram was deployed (https://aiguangyong2025.shinyapps.io/dynnomapp/).
conclusionThe AI-enhanced nomogram integrating clinical and multiparametric MRI data accurately predicts csPCa noninvasively, with R2* significantly improving performance. This tool facilitates personalized clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.